Karpa, Kelly Dowhower
September 2006
Drug Topics;9/18/2006, Vol. 150 Issue 18, special section p9
Trade Publication
The article explains that 34 drugs are in clinical trials for the treatment of glioblastoma multiforme and brain tumors, which means pharmacists will be playing an expanded role in the treatment of these diseases. A monoclonal antibody called bevacizumab inhibits the activity of vascular endothelial growth factor and disrupts a tumor's blood supply. Antineoplastic agents on trial include irinotecan, temozolamide, epidermal growth factor receptor variant III, granulocyte macrophage colony stimulating factor, interleukin-13 receptors, and cintredekin besudotox. INSET: Help for caregivers..


Related Articles

  • Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model. Yi, Diao; Hua, Tian; Lin, Huang; Kui, Chen; Ning, Lin; Wang, Zhuang // Journal of Neuro-Oncology;Aug2011, Vol. 104 Issue 1, p93 

    Using an orthotopic intracerebral model from our established HM55-BGIV-101 tumor line, we investigated the antitumor effect on the angiogenesis and growth of human glioblastoma after treatment with monoclonal antibody DC101 against the vascular endothelial growth factor receptor-2 and monoclonal...

  • Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Taylor, T. E.; Furnari, F. B.; Cavenee, W. K. // Current Cancer Drug Targets;Mar2012, Vol. 12 Issue 3, p197 

    Glioblastoma (glioblastoma multiforme; GBM; WHO Grade IV) accounts for the majority of primary malignant brain tumors in adults. Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in GBM. A range of potential...

  • Curative Potential of GM-CSF-Secreting Tumor Cell Vaccines on Established Orthotopic Liver Tumors: Mechanisms for the Superior Antitumor Activity of Live Tumor Cell Vaccines. Kuo-Feng Tai; Ding-Shinn Chen; Lih-Hwa Hwang // Journal of Biomedical Science;Mar/Apr2004, Vol. 11 Issue 2, p228 

    In preclinical studies, tumor cells genetically engineered to secrete cytokines, hereafter referred to as tumor cell vaccines, can often generate systemic antitumor immunity. This study investigated the therapeutic effects of live or irradiated tumor cell vaccines that secrete...

  • Synergistic Effect of Immunotherapy and Chemotherapy in Cancers: Perspective in High Grade Glioma Treatment. DeAngulo, Guillermo R.; Sun, Wei; Heimberger, Amy B. // Letters in Drug Design & Discovery;Oct2006, Vol. 3 Issue 8, p513 

    Chemotherapy and immunotherapy are two distinct approaches for the treatment for high-grade gliomas. Used independently, neither is curative. However, if the appropriate chemotherapeutic agent is selected and its administration is timed in conjunction with immunotherapy, a potent synergistic...

  • Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. de Groot; M. Gilbert; K. Aldape; K. Hess; T. Hanna; S. Ictech; M. Groves; C. Conrad; H. Colman; V. Puduvalli; V. Levin; W. Yung // Journal of Neuro-Oncology;Oct2008, Vol. 90 Issue 1, p89 

    Abstract  Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus carboplatin and to determine molecular predictors of response. The primary endpoint was progression...

  • Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Miguel, A; Herrero, M J; Sendra, L; Botella, R; Algás, R; Sánchez, M; Aliño, S F // Cancer Gene Therapy;Oct2013, Vol. 20 Issue 10, p576 

    Genetically modified cells have been shown to be one of the most effective cancer vaccine strategies. An evaluation is made of the efficacy of both preventive and therapeutic antitumor vaccines against murine melanoma, using C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and...

  • Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. Koski, Anniina; Kangasn2iemi, Lotta; Escutenaire, Sophie; Pesonen, Sari; Cerullo, Vincenzo; Diaconu, Iulia; Nokisalmi, Petri; Raki, Mari; Rajecki, Maria; Guse, Kilian; Ranki, Tuuli; Oksanen, Minna; Holm, Sirkka-Liisa; Haavisto, Elina; Karioja-Kallio, Aila; Laasonen, Leena; Partanen, Kaarina; Ugolini, Matteo; Helminen, Andreas; Karli, Eerika // Molecular Therapy;Oct2010, Vol. 18 Issue 10, p1874 

    Augmenting antitumor immunity is a promising way to enhance the potency of oncolytic adenoviral therapy. Granulocyte-macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by recruiting natural killer cells and by induction of tumor-specific CD8+ cytotoxic T-lymphocytes....

  • Insmed Advances to Clinic with First Follow-On Biologic, INS-19. Boggs, Jennifer // BioWorld Today;4/17/2008, Vol. 19 Issue 75, p1 

    The article reports that Insmed Inc. has received approval for its follow-on drug, INS-19, from the Medicines and Healthcare Products Regulatory Agency of Great Britain in April 2008. The drug is a recombinant form of granulocyte-colony stimulating factor (G-CSF). Details on the data from Phase...

  • Micromet, Nycomed Deal Could Be Worth €125M.  // Bioworld Week;5/28/2007, Vol. 15 Issue 22, p5 

    The article reports on the collaborate agreement between Micromet Inc. and Nycomed AS on the development of granulocyte macrophage colony-stimulating factor (GM-CSF) antibodies. According to reports, the deal jump-starts the preclinical MT203 program, giving the GM-CSF better probability against...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics